tiprankstipranks
Trending News
More News >
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
US Market
Advertisement

Larimar Therapeutics (LRMR) Stock Forecast & Price Target

Compare
789 Followers
See the Price Targets and Ratings of:

LRMR Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Larimar
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LRMR Stock 12 Month Forecast

Average Price Target

$18.86
▲(382.35% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Larimar Therapeutics in the last 3 months. The average price target is $18.86 with a high forecast of $33.00 and a low forecast of $10.00. The average price target represents a 382.35% change from the last price of $3.91.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","34":"$34","9.25":"$9.25","17.5":"$17.5","25.75":"$25.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,9.25,17.5,25.75,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.44,5.713846153846154,7.987692307692308,10.26153846153846,12.535384615384615,14.80923076923077,17.083076923076923,19.356923076923078,21.630769230769232,23.904615384615386,26.17846153846154,28.452307692307695,30.726153846153846,{"y":33,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.44,4.626153846153846,5.812307692307693,6.998461538461538,8.184615384615384,9.37076923076923,10.556923076923077,11.743076923076922,12.929230769230768,14.115384615384615,15.301538461538462,16.487692307692306,17.673846153846153,{"y":18.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.44,3.9446153846153846,4.44923076923077,4.953846153846154,5.458461538461538,5.963076923076923,6.4676923076923085,6.972307692307693,7.476923076923077,7.981538461538461,8.486153846153847,8.990769230769232,9.495384615384616,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$33.00Average Price Target$18.86Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citizens JMP Analyst forecast on LRMR
Citizens JMP
Citizens JMP
$18
Buy
360.36%
Upside
Reiterated
08/19/25
Larimar Therapeutics (LRMR) Gets a Buy from Citizens JMP
Guggenheim Analyst forecast on LRMR
Guggenheim
Guggenheim
$26
Buy
564.96%
Upside
Reiterated
08/19/25
Guggenheim Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)
Citi
$12
Buy
206.91%
Upside
Reiterated
08/19/25
Buy Rating for Larimar Therapeutics: Strong Phase 3 Progress, Regulatory Alignment, and Market Advantage
Leerink Partners Analyst forecast on LRMR
Joori Park
Leerink Partners
Not Ranked
Leerink Partners
Buy
Reiterated
08/19/25
Positive Outlook for Larimar Therapeutics: Buy Rating Supported by FDA Decisions and Upcoming Trial Data
Truist Financial Analyst forecast on LRMR
Truist Financial
Truist Financial
$18
Buy
360.36%
Upside
Reiterated
08/14/25
Larimar Therapeutics (LRMR) Gets a Buy from Truist FinancialTruist Securities analyst Joon Lee reiterated a Buy rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).
William Blair Analyst forecast on LRMR
William Blair
William Blair
Buy
Reiterated
08/14/25
Promising Data and Optimistic Outlook Drive Buy Rating for Larimar TherapeuticsWe expect the company to focus its presentation on levels of frataxin (FXN) expression in skin, which management feels optimistic will be viewed as a reasonably likely surrogate endpoint for accelerated approval of nomlabofusp based on FDA interactions through CDER’s START program. The prior Phase II clinical data of 50 mg nomlabofusp showed skin FXN levels approximating those of 50% of healthy volunteers (asymptomatic range), which we view as clearly exceeding the bar for success here, and further transcriptomic and lipidomic data gathered remain supportive. The agency has also been provided with nonclinical data of nomlabofusp showing human FXN expression in heart, skeletal muscle, and dorsal root ganglion that correlates with skin FXN expression levels in mouse models of FA and rats (De Toni F et al., 2025. AAPS).
LifeSci Capital Analyst forecast on LRMR
LifeSci Capital
LifeSci Capital
$33
Buy
743.99%
Upside
Reiterated
08/14/25
Promising Advancements and Strategic Positioning Drive Buy Rating for Larimar Therapeutics
JonesTrading Analyst forecast on LRMR
JonesTrading
JonesTrading
$12$10
Buy
155.75%
Upside
Reiterated
08/04/25
JonesTrading Remains a Buy on Larimar Therapeutics (LRMR)Jones Trading analyst Catherine Novack lowered the price target on Larimar Therapeutics (NASDAQ: LRMR) to $10.00 (from $12.00) while maintaining a Buy rating.
Wedbush
$17$15
Buy
283.63%
Upside
Reiterated
06/24/25
Larimar Therapeutics price target lowered to $15 from $17 at WedbushLarimar Therapeutics price target lowered to $15 from $17 at Wedbush
Robert W. Baird Analyst forecast on LRMR
Robert W. Baird
Robert W. Baird
$13$10
Buy
155.75%
Upside
Reiterated
03/25/25
Larimar Therapeutics price target lowered to $10 from $13 at BairdLarimar Therapeutics price target lowered to $10 from $13 at Baird
H.C. Wainwright Analyst forecast on LRMR
H.C. Wainwright
H.C. Wainwright
$15$16
Buy
309.21%
Upside
Reiterated
03/25/25
Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp's Potential in Treating Friedreich's Ataxia
Oppenheimer
$26
Buy
564.96%
Upside
Reiterated
12/17/24
Oppenheimer Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citizens JMP Analyst forecast on LRMR
Citizens JMP
Citizens JMP
$18
Buy
360.36%
Upside
Reiterated
08/19/25
Larimar Therapeutics (LRMR) Gets a Buy from Citizens JMP
Guggenheim Analyst forecast on LRMR
Guggenheim
Guggenheim
$26
Buy
564.96%
Upside
Reiterated
08/19/25
Guggenheim Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)
Citi
$12
Buy
206.91%
Upside
Reiterated
08/19/25
Buy Rating for Larimar Therapeutics: Strong Phase 3 Progress, Regulatory Alignment, and Market Advantage
Leerink Partners Analyst forecast on LRMR
Joori Park
Leerink Partners
Not Ranked
Leerink Partners
Buy
Reiterated
08/19/25
Positive Outlook for Larimar Therapeutics: Buy Rating Supported by FDA Decisions and Upcoming Trial Data
Truist Financial Analyst forecast on LRMR
Truist Financial
Truist Financial
$18
Buy
360.36%
Upside
Reiterated
08/14/25
Larimar Therapeutics (LRMR) Gets a Buy from Truist FinancialTruist Securities analyst Joon Lee reiterated a Buy rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).
William Blair Analyst forecast on LRMR
William Blair
William Blair
Buy
Reiterated
08/14/25
Promising Data and Optimistic Outlook Drive Buy Rating for Larimar TherapeuticsWe expect the company to focus its presentation on levels of frataxin (FXN) expression in skin, which management feels optimistic will be viewed as a reasonably likely surrogate endpoint for accelerated approval of nomlabofusp based on FDA interactions through CDER’s START program. The prior Phase II clinical data of 50 mg nomlabofusp showed skin FXN levels approximating those of 50% of healthy volunteers (asymptomatic range), which we view as clearly exceeding the bar for success here, and further transcriptomic and lipidomic data gathered remain supportive. The agency has also been provided with nonclinical data of nomlabofusp showing human FXN expression in heart, skeletal muscle, and dorsal root ganglion that correlates with skin FXN expression levels in mouse models of FA and rats (De Toni F et al., 2025. AAPS).
LifeSci Capital Analyst forecast on LRMR
LifeSci Capital
LifeSci Capital
$33
Buy
743.99%
Upside
Reiterated
08/14/25
Promising Advancements and Strategic Positioning Drive Buy Rating for Larimar Therapeutics
JonesTrading Analyst forecast on LRMR
JonesTrading
JonesTrading
$12$10
Buy
155.75%
Upside
Reiterated
08/04/25
JonesTrading Remains a Buy on Larimar Therapeutics (LRMR)Jones Trading analyst Catherine Novack lowered the price target on Larimar Therapeutics (NASDAQ: LRMR) to $10.00 (from $12.00) while maintaining a Buy rating.
Wedbush
$17$15
Buy
283.63%
Upside
Reiterated
06/24/25
Larimar Therapeutics price target lowered to $15 from $17 at WedbushLarimar Therapeutics price target lowered to $15 from $17 at Wedbush
Robert W. Baird Analyst forecast on LRMR
Robert W. Baird
Robert W. Baird
$13$10
Buy
155.75%
Upside
Reiterated
03/25/25
Larimar Therapeutics price target lowered to $10 from $13 at BairdLarimar Therapeutics price target lowered to $10 from $13 at Baird
H.C. Wainwright Analyst forecast on LRMR
H.C. Wainwright
H.C. Wainwright
$15$16
Buy
309.21%
Upside
Reiterated
03/25/25
Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp's Potential in Treating Friedreich's Ataxia
Oppenheimer
$26
Buy
564.96%
Upside
Reiterated
12/17/24
Oppenheimer Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Larimar Therapeutics

1 Month
xxx
Success Rate
6/10 ratings generated profit
60%
Average Return
+3.75%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +3.75% per trade.
3 Months
xxx
Success Rate
13/25 ratings generated profit
52%
Average Return
+20.49%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.00% of your transactions generating a profit, with an average return of +20.49% per trade.
1 Year
Jonathan WollebenCitizens JMP
Success Rate
16/25 ratings generated profit
64%
Average Return
+30.44%
reiterated a buy rating 5 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 64.00% of your transactions generating a profit, with an average return of +30.44% per trade.
2 Years
xxx
Success Rate
13/25 ratings generated profit
52%
Average Return
+38.84%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 52.00% of your transactions generating a profit, with an average return of +38.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LRMR Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
12
11
10
7
17
Buy
4
6
5
5
5
Hold
0
2
2
2
0
Sell
4
4
3
0
0
Strong Sell
0
0
0
0
0
total
20
23
20
14
22
In the current month, LRMR has received 22 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LRMR average Analyst price target in the past 3 months is 18.86.
Each month's total comprises the sum of three months' worth of ratings.

LRMR Financial Forecast

LRMR Earnings Forecast

Next quarter’s earnings estimate for LRMR is -$0.41 with a range of -$0.50 to -$0.33. The previous quarter’s EPS was -$0.41. LRMR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.04% of the time in the same period. In the last calendar year LRMR has Outperformed its overall industry.
Next quarter’s earnings estimate for LRMR is -$0.41 with a range of -$0.50 to -$0.33. The previous quarter’s EPS was -$0.41. LRMR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.04% of the time in the same period. In the last calendar year LRMR has Outperformed its overall industry.
No data currently available

LRMR Sales Forecast

Next quarter’s sales forecast for LRMR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. LRMR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.88% of the time in the same period. In the last calendar year LRMR has Preformed in-line its overall industry.
Next quarter’s sales forecast for LRMR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. LRMR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.88% of the time in the same period. In the last calendar year LRMR has Preformed in-line its overall industry.

LRMR Stock Forecast FAQ

What is LRMR’s average 12-month price target, according to analysts?
Based on analyst ratings, Larimar Therapeutics, Inc.’s 12-month average price target is 18.86.
    What is LRMR’s upside potential, based on the analysts’ average price target?
    Larimar Therapeutics, Inc. has 382.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is LRMR a Buy, Sell or Hold?
          Larimar Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Larimar Therapeutics, Inc.’s price target?
            The average price target for Larimar Therapeutics, Inc. is 18.86. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $33.00 ,the lowest forecast is $10.00. The average price target represents 382.35% Increase from the current price of $3.91.
              What do analysts say about Larimar Therapeutics, Inc.?
              Larimar Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of LRMR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis